NuScale 10-Qquarter ended 2026-09-30

Executive Summary

NuScale develops modular nuclear reactors for power-project developers and utilities, currently earning revenue from engineering, licensing and services rather than reactor sales. It is moving its approved reactor design toward production, with commercialization centered on ENTRA1-led U.S. projects and Romania’s RoPower project. Q3 revenue fell 97% as earlier project work did not recur, while narrower losses mainly reflected a large prior-year milestone charge rather than operating improvement. Equity financing has strengthened its resources, but investors still face the central uncertainty: whether prospective projects become binding, funded reactor orders before commercialization consumes substantially more capital.

What's Happening in the Business

NuScale is spending on production readiness before securing binding module-delivery contracts. Its 77-megawatt reactor design received Nuclear Regulatory Commission approval in May 2025; the current effort is component development, manufacturing preparation and project delivery. June contracts with Paragon Energy Solutions totaled $25.8M for protection-system development and supply-chain readiness. An October Doosan contract subsequently supported physical production of an advanced reactor component.

Commercial progress remains conditional. ENTRA1 and the Tennessee Valley Authority announced a non-binding collaboration for up to 6 gigawatts of nuclear generation, dependent on power purchase agreements. ENTRA1 is NuScale’s exclusive global commercialization partner, but can decide whether to select or purchase NuScale technology; NuScale also needs its consent to pursue opportunities independently. That gives the partner considerable influence over access to customers.

Romania approved the Doicești project investment decision on 2/12/2026, permitting further development work. However, RoPower—NuScale’s sole international customer—must secure financing before signing the next engineering and construction preparation contract. NuScale expects work to resume afterward. Its earlier engineering scope ended in late 2025, explaining why project advancement has not yet translated into recurring revenue.

Key Financial Highlights

Q3 and nine months ended 9/30/2026; changes are Y/Y.

• Development spending: R&D reached $18.0M in Q3, +63%, and $49.2M for 9M, +54%; module-related work added $19.7M to nine-month costs, partly offset by lower regulatory and testing spending after design approval.
• Investment income: Q3 $19.1M and 9M $43.9M reflected larger invested balances and higher interest rates, not stronger reactor commercialization.
• Operating cash use: 9M $401M, +57%, vs total net loss (incl. noncontrolling interests) of $142M. A $260M payment settled an earlier ENTRA1 milestone obligation, consuming cash without a matching current-period expense; lower customer collections and material prepayments also contributed.
• Financing and dilution: Share issuance generated $984M net in 9M vs $562M a year earlier. Class A shares outstanding increased 29% from year-end to 411M, reflecting financing and ownership conversions. No shares were sold in Q3; an August agreement permits another $750M of potential sales.
• Funding and commitments: Cash and investments totaled $1.86B, with no debt. Contractual commitments were $170M—42% of nine-month operating cash use—including $110M due in 2027. Additional ENTRA1 milestone payments remain contingent on future agreements and are not accrued.

Risk Assessment

• Commercial conversion and partner dependence: ENTRA1’s discretion over purchasing and NuScale’s restricted ability to pursue independent opportunities could delay orders despite continued commercialization spending.
• Customer financing: RoPower’s financing requirement and the U.S. collaboration’s dependence on power purchase agreements leave prospective revenue exposed to decisions outside NuScale’s control.
• Cash consumption and dilution: Minimal revenue, production-readiness spending and potential additional milestone obligations could require further equity issuance despite the substantial investment portfolio.
• Securities litigation: A class action challenges statements about ENTRA1’s experience and capabilities; NuScale sought dismissal in September, but potential losses from this and related derivative actions cannot be estimated.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: FY2025 10-K.

What to Watch

• U.S. order conversion: The ENTRA1 collaboration remains non-binding. Power purchase agreements and binding module contracts would validate commercialization; continued announcements without contracts would leave spending ahead of demand.
• Romania restart: RoPower has investment-decision approval but still needs financing and the next contract. Resumed paid engineering work would demonstrate progress; further delays would prolong the revenue gap.
• Manufacturing readiness: Paragon development and Doosan component work are underway. Later filings should show completed technical milestones progressing toward customer deliveries rather than readiness spending without orders.
• Cash and dilution: The new share-sale authorization provides financing flexibility. Progress means funded customer work begins supporting commercialization costs; persistent cash consumption accompanied by additional issuance would increase existing investors’ dilution.